Official Title: “An Open-Label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease”

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Study Primary Completion Date: December 2009

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Intervention(s) in this Clinical Trial

• Drug: Escitalopram
  • See Detailed Description.

Primary Measures

• Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.
  • Time Frame: Unspecified
    Safety Issue?: No

Secondary Measures

• Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study
  • Time Frame: Unspecified
    Safety Issue?: No

Inclusion Criteria:

• > 50 years
• Male & female
• Alzheimer's disease
• Depressive episode

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 50 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: University of British Columbia

Overall Clinical Trial Officials and Contacts

Kiran Rabheru, MD Principal Investigator University of British Columbia  

Overall Contact: Mario McKenna 604-875-4111 mario.mckenna@vch.ca

Information obtained from ClinicalTrials.gov on November 20, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00488670

Study ID Number: H07-00050

ClinicalTrials.gov Identifier: NCT00488670

Health Authority: Canada: Health Canada